New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 9, 2014
07:42 EDTMYOSMYOS announces approval for listing on NASDAQ
MYOS announced that it has received approval for the listing of its common stock on the NASDAQ Capital Market. The common stock is expected to begin trading on the NASDAQ at market open on July 10 under its existing ticker symbol, MYOS. The common stock will continue to trade on the OTC Bulletin Board until market close on July 9.
News For MYOS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 22, 2015
08:12 EDTMYOSMYOS study of Fortetropin mechanism of action shows regulatory effects
MYOS announced that its mechanism of action studies have identified three key molecular signaling pathways in which Fortetropin exhibits regulatory effects. In addition to reducing serum myostatin levels, MYOS recently completed a preclinical mechanism of action study that demonstrated Fortetropin's activity in mTOR and Ubiquitin, two other crucial signaling pathways in the growth and maintenance of healthy muscle. In addition to myostatin regulation, MYOS' preclinical data also showed that Fortetropin up-regulates the mTOR regulatory pathway. The mTOR pathway is responsible for production of a protein kinase related to cell growth and proliferation that increases skeletal muscle mass. Up-regulation of the mTOR pathway is important in preventing muscle atrophy. Fortetropin's ability to affect the mTOR pathway may have a significant impact in treating patients suffering from degenerative muscle diseases and suggests that Fortetropin-based products may help slow muscle loss secondary to immobility and denervation. Finally, the company's recent animal model study demonstrated that Fortetropin acts to reduce the synthesis of proteins in the Ubiquitin pathway, a highly selective, tightly regulated system that serves to activate muscle breakdown. Over-production in the Ubiquitin pathway is responsible for muscle degradation. Fortetropin's ability to regulate production in the Ubiquitin pathway may have significant implications for repairing age-related muscle loss and for patients suffering from chronic diseases causing cachexia.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use